Is there a role for docetaxel for men with high risk prostate cancer receiving radiation and androgen deprivation therapy?
Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, non-metastatic patients?
Answer from: Medical Oncologist at Academic Institution
Standard of care for high risk localized prostate cancer remains radiation and long term androgen deprivation therapy. To date, there are no trials that have demonstrated an overall survival benefit with the addition of chemotherapy. Given the potential toxicity of adding chemotherapy, this should...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
NRG RTOG 0521 has now been published in JCO. I may be biased (since I am study PI) but it seems reasonable to infer a small survival advantage to adjuvant docetaxel in a quite high risk prostate cancer population receiving radiotherapy and ADT. See figure 2A in the paper. Of course, one can view the...
Comments
Radiation Oncologist at Northeast Alabama Regional Medical Center
Howard (feel free not to answer this, as I would i...
Howard (feel free not to answer this, as I would i...
Radiation Oncologist at Cedars-Sinai Medical Center
The one-sided p-value was pragmatic (sample size) ...
The one-sided p-value was pragmatic (sample size) ...
Medical Oncologist at Oncology Institute of Hope and Innovation
Howard, Would you provide the same guidance for ...
Howard, Would you provide the same guidance for ...
Radiation Oncologist at Cedars-Sinai Medical Center
I assume that the risk of docetaxel varies with ag...
I assume that the risk of docetaxel varies with ag...
Answer from: Radiation Oncologist at Community Practice
Since the early analysis of RTOG 0521 showed a survival advantage (http://meetinglibrary.asco.org/content/144388-156), we have been referring very high risk patients for a discussion about adjuvant chemotherapy to medical oncology.
Answer from: Radiation Oncologist at Community Practice
It looks the recent update of the NCCN Guidelines has removed the footnote of offering high risk patients taxotere with adt after completion of radiation, stating more fu is needed.